Evidence map›Paper›PMID 36909752›Full record

ArticleRSC advances2023

1,10-Phenanthroline-based periodic mesoporous organosilica: from its synthesis to its application in the cobalt-catalyzed alkyne hydrosilylation.

Xiao-Tao Lin, Yusuke Ishizaka, Yoshifumi Maegawa, Katsuhiko Takeuchi, Shinji Inagaki, Kazuhiro Matsumoto, Jun-Chul Choi

Abstract read
In one paragraph

Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiao-Tao LinNational Institute of Advanced Industrial Science and Technology (AIST) Tsukuba Central 5, 1-1-1 Higashi Tsukuba Ibaraki 305-8565 Japan kazuhiro.matsumoto@aist.go.jp junchul.choi@aist.go.jp.
Yusuke IshizakaNational Institute of Advanced Industrial Science and Technology (AIST) Tsukuba Central 5, 1-1-1 Higashi Tsukuba Ibaraki 305-8565 Japan kazuhiro.matsumoto@aist.go.jp junchul.choi@aist.go.jp.ORCID https://orcid.org/0000-0002-3558-5243
Yoshifumi MaegawaToyota Central R&D Labs., Inc. Nagakute Aichi 480-1192 Japan.
Katsuhiko TakeuchiNational Institute of Advanced Industrial Science and Technology (AIST) Tsukuba Central 5, 1-1-1 Higashi Tsukuba Ibaraki 305-8565 Japan kazuhiro.matsumoto@aist.go.jp junchul.choi@aist.go.jp.ORCID https://orcid.org/0000-0002-2720-5394
Shinji InagakiNational Institute of Advanced Industrial Science and Technology (AIST) Tsukuba Central 5, 1-1-1 Higashi Tsukuba Ibaraki 305-8565 Japan kazuhiro.matsumoto@aist.go.jp junchul.choi@aist.go.jp.ORCID https://orcid.org/0000-0003-0405-5511
Kazuhiro MatsumotoNational Institute of Advanced Industrial Science and Technology (AIST) Tsukuba Central 5, 1-1-1 Higashi Tsukuba Ibaraki 305-8565 Japan kazuhiro.matsumoto@aist.go.jp junchul.choi@aist.go.jp.ORCID https://orcid.org/0000-0003-1580-8822
Jun-Chul ChoiNational Institute of Advanced Industrial Science and Technology (AIST) Tsukuba Central 5, 1-1-1 Higashi Tsukuba Ibaraki 305-8565 Japan kazuhiro.matsumoto@aist.go.jp junchul.choi@aist.go.jp.ORCID https://orcid.org/0000-0002-7049-5032

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

1,10-Phenanthroline (Phen) is a typical ligand for metal complexation and various metal/Phen complexes have been applied as a catalyst in several organic transformations. This study reports the synthesis of a Phen-based periodic mesoporous organosilica (Phen-PMO) with the Phen moieties being directly incorporated into the organosilica framework. The Phen-PMO precursor, 3,8-bis[(triisopropoxysilyl)methyl]-1,10-phenanthroline (1a), was prepared

Identifiers

PMID36909752
PMCPMC9996227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.